<p>InflaRx（納斯達克代碼：IFRX - 獲取免費報告）於週三發佈了季度財報。該公司報告本季度每股收益為（$0.09），超出分析師一致預期的（$0.17）$0.08，FiscalAI 報道。</p>
<h2>InflaRx 股價上漲 26.9%</h2>
<p>週三，納斯達克代碼：IFRX 的股票上漲了 $0.53，達到 $2.50。該公司的交易量為 18,208,689 股，而其平均交易量為 1,612,826 股。InflaRx 的 12 個月最低價為 $0.71，最高價為 $2.86。該公司的 50 日簡單移動平均為 $1.16，200 日簡單移動平均為 $1.12。該股票的市值為 1.8073 億美元，市盈率為 -3.29，貝塔值為 2.42。</p>
<h2>機構資金流入和流出</h2>
<p>機構投資者最近對該公司的持倉進行了調整。Cubist Systematic Strategies LLC 在第一季度將其在 InflaRx 的持股增加了 33.9%。Cubist Systematic Strategies LLC 目前擁有 30,053 股該公司的股票，價值 $31,000，此前在上個季度增持了 7,616 股。HRT Financial LP 在第四季度購買了 InflaRx 的新頭寸，價值約 $47,000。Insigneo Advisory Services LLC 在第四季度購買了 InflaRx 的新頭寸，價值約 $61,000。Quadrature Capital Ltd 在第四季度購買了 InflaRx 的新頭寸，價值約 $104,000。最後，XTX Topco Ltd 在第四季度購買了 InflaRx 的新股份，價值約 $135,000。機構投資者持有該公司 42.39% 的股票。</p>
<h2>華爾街分析師觀點</h2>
<p>一些研究分析師最近對該公司發表了看法。Oppenheimer 在 4 月 24 日的研究報告中開始覆蓋 InflaRx。他們給予該公司 “跑贏大盤” 的評級，並設定了 $5.00 的目標價。Guggenheim 在 4 月 21 日的研究報告中重申了對 InflaRx 的 “買入” 評級，並設定了 $14.00 的目標價。最後，Weiss Ratings 在 3 月 27 日的研究報告中重申了對 InflaRx 的 “賣出（d-）” 評級。四位投資分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，平均目標價為 $5.80。</p>
<p><strong>獲取我們關於 IFRX 的最新股票報告</strong></p>
<h2>InflaRx 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>InflaRx N.V. 是一家臨牀階段的生物製藥公司，專注於發現、開發和商業化針對補體系統的新療法，重點關注補體-1a（C5a）通路。該公司的主要產品候選藥物 vilobelimab（IFX-1）是一種單克隆抗體，旨在選擇性抑制 C5a，這是一種與多種自身免疫和炎症疾病相關的強效促炎肽。InflaRx 旨在通過推進對如膿皰性汗腺炎、壞死性皮膚病和其他罕見且嚴重的炎症性疾病的治療，來滿足高度未滿足的醫療需求。</p>
<p>Vilobelimab 已在多個 II 期臨牀試驗中進行評估，證明其在降低關鍵炎症標誌物和改善臨牀結果方面的概念驗證。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而不是 InflaRx</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUZSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUZSWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 $1,000 在 InflaRx 嗎？</h2>
<p>在你考慮 InflaRx 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 InflaRx 並不在名單上。</p>
<p>雖然 InflaRx 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

IFRX

納斯達克生物科技指數 ETF - iShares Nasdaq

IBBQ

標普生物技術 ETF - SPDR

<p>InflaRx（納斯達克代碼：IFRX）報告季度每股收益為（$0.09），超出預期的（$0.17）$0.08。在公告發布後，股價上漲 26.9%，達到$2.50。機構投資者持有該股票的 42.39%，並且最近有幾筆收購。分析師的評級不一，平均目標價為$5.80。InflaRx 專注於開發針對補體系統的療法，特別是用於自身免疫和炎症性疾病</p>

<p>InflaRx (NASDAQ:IFRX - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.08, FiscalAI reports.</p>
<div class="lb-trans"><p>InflaRx（納斯達克代碼：IFRX - 獲取免費報告）於週三發佈了季度財報。該公司報告本季度每股收益為（$0.09），超出分析師一致預期的（$0.17）$0.08，FiscalAI 報道。</p>
</div><h2>InflaRx Trading Up 26.9%</h2>
<div class="lb-trans"><h2>InflaRx 股價上漲 26.9%</h2>
</div><p>Shares of NASDAQ:IFRX traded up $0.53 during trading on Wednesday, reaching $2.50. The company's stock had a trading volume of 18,208,689 shares, compared to its average volume of 1,612,826. InflaRx has a 12 month low of $0.71 and a 12 month high of $2.86. The firm's 50 day simple moving average is $1.16 and its two-hundred day simple moving average is $1.12. The stock has a market capitalization of $180.73 million, a PE ratio of -3.29 and a beta of 2.42.</p>
<div class="lb-trans"><p>週三，納斯達克代碼：IFRX 的股票上漲了 $0.53，達到 $2.50。該公司的交易量為 18,208,689 股，而其平均交易量為 1,612,826 股。InflaRx 的 12 個月最低價為 $0.71，最高價為 $2.86。該公司的 50 日簡單移動平均為 $1.16，200 日簡單移動平均為 $1.12。該股票的市值為 1.8073 億美元，市盈率為 -3.29，貝塔值為 2.42。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Institutional investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC lifted its holdings in shares of InflaRx by 33.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company's stock valued at $31,000 after acquiring an additional 7,616 shares during the last quarter. HRT Financial LP bought a new position in shares of InflaRx in the 4th quarter valued at about $47,000. Insigneo Advisory Services LLC bought a new position in shares of InflaRx in the 4th quarter valued at about $61,000. Quadrature Capital Ltd bought a new position in shares of InflaRx in the 4th quarter valued at about $104,000. Finally, XTX Topco Ltd bought a new stake in InflaRx in the fourth quarter worth about $135,000. Institutional investors own 42.39% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者最近對該公司的持倉進行了調整。Cubist Systematic Strategies LLC 在第一季度將其在 InflaRx 的持股增加了 33.9%。Cubist Systematic Strategies LLC 目前擁有 30,053 股該公司的股票，價值 $31,000，此前在上個季度增持了 7,616 股。HRT Financial LP 在第四季度購買了 InflaRx 的新頭寸，價值約 $47,000。Insigneo Advisory Services LLC 在第四季度購買了 InflaRx 的新頭寸，價值約 $61,000。Quadrature Capital Ltd 在第四季度購買了 InflaRx 的新頭寸，價值約 $104,000。最後，XTX Topco Ltd 在第四季度購買了 InflaRx 的新股份，價值約 $135,000。機構投資者持有該公司 42.39% 的股票。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>A number of research analysts have recently weighed in on the company. Oppenheimer assumed coverage on InflaRx in a research report on Friday, April 24th. They set an &#34;outperform&#34; rating and a $5.00 price objective for the company. Guggenheim restated a &#34;buy&#34; rating and set a $14.00 price objective on shares of InflaRx in a research report on Tuesday, April 21st. Finally, Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of InflaRx in a research report on Friday, March 27th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $5.80.</p>
<div class="lb-trans"><p>一些研究分析師最近對該公司發表了看法。Oppenheimer 在 4 月 24 日的研究報告中開始覆蓋 InflaRx。他們給予該公司 “跑贏大盤” 的評級，並設定了 $5.00 的目標價。Guggenheim 在 4 月 21 日的研究報告中重申了對 InflaRx 的 “買入” 評級，並設定了 $14.00 的目標價。最後，Weiss Ratings 在 3 月 27 日的研究報告中重申了對 InflaRx 的 “賣出（d-）” 評級。四位投資分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，平均目標價為 $5.80。</p>
</div><p><strong>Get Our Latest Stock Report on IFRX</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 IFRX 的最新股票報告</strong></p>
</div><h2>InflaRx Company Profile</h2>
<div class="lb-trans"><h2>InflaRx 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company's lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.</p>
<div class="lb-trans"><p>InflaRx N.V. 是一家臨牀階段的生物製藥公司，專注於發現、開發和商業化針對補體系統的新療法，重點關注補體-1a（C5a）通路。該公司的主要產品候選藥物 vilobelimab（IFX-1）是一種單克隆抗體，旨在選擇性抑制 C5a，這是一種與多種自身免疫和炎症疾病相關的強效促炎肽。InflaRx 旨在通過推進對如膿皰性汗腺炎、壞死性皮膚病和其他罕見且嚴重的炎症性疾病的治療，來滿足高度未滿足的醫療需求。</p>
</div><p>Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.</p>
<div class="lb-trans"><p>Vilobelimab 已在多個 II 期臨牀試驗中進行評估，證明其在降低關鍵炎症標誌物和改善臨牀結果方面的概念驗證。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than InflaRx</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 InflaRx</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUZSWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=IFRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in InflaRx Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 InflaRx 嗎？</h2>
</div><p>Before you consider InflaRx, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 InflaRx 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InflaRx wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 InflaRx 並不在名單上。</p>
</div><p>While InflaRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 InflaRx 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

InflaRx (NASDAQ:IFRX) 公佈了財報，每股收益超出預期 0.08 美元